Selected research
Market Structure
Global Gonadotropin-releasing Hormone Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Gonadotropin-releasing Hormone Agonist market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Gonadotropin-releasing Hormone Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Gonadotropin-releasing Hormone Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Gonadotropin-releasing Hormone Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Gonadotropin-releasing Hormone Agonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Gonadotropin-releasing Hormone Agonist include Endo, Ferring, Ipsen, LIVZON, TerSera Therapeutics, AstraZeneca, AbbVie, Sanofi and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Gonadotropin-releasing Hormone Agonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Gonadotropin-releasing Hormone Agonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Gonadotropin-releasing Hormone Agonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gonadotropin-releasing Hormone Agonist market size, projected growth trends, production technologies, key applications, and end-use industries.
Gonadotropin-releasing Hormone Agonist Segment by Company
Endo
Ferring
Ipsen
LIVZON
TerSera Therapeutics
AstraZeneca
AbbVie
Sanofi
Takeda
Gonadotropin-releasing Hormone Agonist Segment by Type
Histrelin
Taltirelin
Leuprorelin
Goserelin
Other
Gonadotropin-releasing Hormone Agonist Segment by Application
Hospital
Pharmacy
Other
Gonadotropin-releasing Hormone Agonist Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gonadotropin-releasing Hormone Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gonadotropin-releasing Hormone Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gonadotropin-releasing Hormone Agonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Gonadotropin-releasing Hormone Agonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gonadotropin-releasing Hormone Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Gonadotropin-releasing Hormone Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Gonadotropin-releasing Hormone Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Histrelin
- Taltirelin
- Leuprorelin
- Goserelin
- Other
Applications
- Hospital
- Pharmacy
- Other
Companies covered
- Endo
- Ferring
- Ipsen
- LIVZON
- TerSera Therapeutics
- AstraZeneca
- AbbVie
- Sanofi
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Gonadotropin-releasing Hormone Agonist Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Gonadotropin-releasing Hormone Agonist Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Gonadotropin-releasing Hormone Agonist Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Gonadotropin-releasing Hormone Agonist Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Gonadotropin-releasing Hormone Agonist Market Dynamics
- 2.1 Gonadotropin-releasing Hormone Agonist Industry Trends
- 2.2 Gonadotropin-releasing Hormone Agonist Industry Drivers
- 2.3 Gonadotropin-releasing Hormone Agonist Industry Opportunities and Challenges
- 2.4 Gonadotropin-releasing Hormone Agonist Industry Restraints
3 Gonadotropin-releasing Hormone Agonist Market by Manufacturers
- 3.1 Global Gonadotropin-releasing Hormone Agonist Revenue by Manufacturers (2021-2026)
- 3.2 Global Gonadotropin-releasing Hormone Agonist Sales by Manufacturers (2021-2026)
- 3.3 Global Gonadotropin-releasing Hormone Agonist Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Gonadotropin-releasing Hormone Agonist Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Gonadotropin-releasing Hormone Agonist Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Gonadotropin-releasing Hormone Agonist Manufacturers, Product Type & Application
- 3.7 Global Gonadotropin-releasing Hormone Agonist Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Gonadotropin-releasing Hormone Agonist Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Gonadotropin-releasing Hormone Agonist Players Market Share by Revenue in 2025
- 3.8.3 2025 Gonadotropin-releasing Hormone Agonist Tier 1, Tier 2, and Tier 3
4 Gonadotropin-releasing Hormone Agonist Market by Type
- 4.1 Gonadotropin-releasing Hormone Agonist Type Introduction
- 4.1.1 Histrelin
- 4.1.2 Taltirelin
- 4.1.3 Leuprorelin
- 4.1.4 Goserelin
- 4.1.5 Other
- 4.2 Global Gonadotropin-releasing Hormone Agonist Sales by Type
- 4.2.1 Global Gonadotropin-releasing Hormone Agonist Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Gonadotropin-releasing Hormone Agonist Sales by Type (2021-2032)
- 4.2.3 Global Gonadotropin-releasing Hormone Agonist Sales Market Share by Type (2021-2032)
- 4.3 Global Gonadotropin-releasing Hormone Agonist Revenue by Type
- 4.3.1 Global Gonadotropin-releasing Hormone Agonist Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Gonadotropin-releasing Hormone Agonist Revenue by Type (2021-2032)
- 4.3.3 Global Gonadotropin-releasing Hormone Agonist Revenue Market Share by Type (2021-2032)
5 Gonadotropin-releasing Hormone Agonist Market by Application
- 5.1 Gonadotropin-releasing Hormone Agonist Application Introduction
- 5.1.1 Hospital
- 5.1.2 Pharmacy
- 5.1.3 Other
- 5.2 Global Gonadotropin-releasing Hormone Agonist Sales by Application
- 5.2.1 Global Gonadotropin-releasing Hormone Agonist Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Gonadotropin-releasing Hormone Agonist Sales by Application (2021-2032)
- 5.2.3 Global Gonadotropin-releasing Hormone Agonist Sales Market Share by Application (2021-2032)
- 5.3 Global Gonadotropin-releasing Hormone Agonist Revenue by Application
- 5.3.1 Global Gonadotropin-releasing Hormone Agonist Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Gonadotropin-releasing Hormone Agonist Revenue by Application (2021-2032)
- 5.3.3 Global Gonadotropin-releasing Hormone Agonist Revenue Market Share by Application (2021-2032)
6 Global Gonadotropin-releasing Hormone Agonist Sales by Region
- 6.1 Global Gonadotropin-releasing Hormone Agonist Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Gonadotropin-releasing Hormone Agonist Sales by Region (2021-2032)
- 6.2.1 Global Gonadotropin-releasing Hormone Agonist Sales by Region (2021-2026)
- 6.2.2 Global Gonadotropin-releasing Hormone Agonist Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Gonadotropin-releasing Hormone Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Gonadotropin-releasing Hormone Agonist Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Gonadotropin-releasing Hormone Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Gonadotropin-releasing Hormone Agonist Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Gonadotropin-releasing Hormone Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Gonadotropin-releasing Hormone Agonist Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Gonadotropin-releasing Hormone Agonist Revenue by Region
- 7.1 Global Gonadotropin-releasing Hormone Agonist Revenue by Region
- 7.1.1 Global Gonadotropin-releasing Hormone Agonist Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Gonadotropin-releasing Hormone Agonist Revenue by Region (2021-2026)
- 7.1.3 Global Gonadotropin-releasing Hormone Agonist Revenue by Region (2027-2032)
- 7.1.4 Global Gonadotropin-releasing Hormone Agonist Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Gonadotropin-releasing Hormone Agonist Revenue (2021-2032)
- 7.2.2 North America Gonadotropin-releasing Hormone Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Gonadotropin-releasing Hormone Agonist Revenue (2021-2032)
- 7.3.2 Europe Gonadotropin-releasing Hormone Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Gonadotropin-releasing Hormone Agonist Revenue (2021-2032)
- 7.4.2 Asia-Pacific Gonadotropin-releasing Hormone Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Endo
- 8.1.1 Endo Company Information
- 8.1.2 Endo Business Overview
- 8.1.3 Endo Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Endo Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.1.5 Endo Recent Developments
- 8.2 Ferring
- 8.2.1 Ferring Company Information
- 8.2.2 Ferring Business Overview
- 8.2.3 Ferring Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Ferring Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.2.5 Ferring Recent Developments
- 8.3 Ipsen
- 8.3.1 Ipsen Company Information
- 8.3.2 Ipsen Business Overview
- 8.3.3 Ipsen Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Ipsen Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.3.5 Ipsen Recent Developments
- 8.4 LIVZON
- 8.4.1 LIVZON Company Information
- 8.4.2 LIVZON Business Overview
- 8.4.3 LIVZON Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 LIVZON Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.4.5 LIVZON Recent Developments
- 8.5 TerSera Therapeutics
- 8.5.1 TerSera Therapeutics Company Information
- 8.5.2 TerSera Therapeutics Business Overview
- 8.5.3 TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.5.5 TerSera Therapeutics Recent Developments
- 8.6 AstraZeneca
- 8.6.1 AstraZeneca Company Information
- 8.6.2 AstraZeneca Business Overview
- 8.6.3 AstraZeneca Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 AstraZeneca Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.6.5 AstraZeneca Recent Developments
- 8.7 AbbVie
- 8.7.1 AbbVie Company Information
- 8.7.2 AbbVie Business Overview
- 8.7.3 AbbVie Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 AbbVie Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.7.5 AbbVie Recent Developments
- 8.8 Sanofi
- 8.8.1 Sanofi Company Information
- 8.8.2 Sanofi Business Overview
- 8.8.3 Sanofi Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Sanofi Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.8.5 Sanofi Recent Developments
- 8.9 Takeda
- 8.9.1 Takeda Company Information
- 8.9.2 Takeda Business Overview
- 8.9.3 Takeda Gonadotropin-releasing Hormone Agonist Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Takeda Gonadotropin-releasing Hormone Agonist Product Portfolio
- 8.9.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Gonadotropin-releasing Hormone Agonist Value Chain Analysis
- 9.1.1 Gonadotropin-releasing Hormone Agonist Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Gonadotropin-releasing Hormone Agonist Production Mode & Process
- 9.2 Gonadotropin-releasing Hormone Agonist Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Gonadotropin-releasing Hormone Agonist Distributors
- 9.2.3 Gonadotropin-releasing Hormone Agonist Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst